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Abstract
Individualized approaches to prognosis are crucial to effective management of cancer patients. We developed a
methodology to assign individualized 5-year disease-specific death probabilities to 1,222 patients with melanoma and to
1,225 patients with breast cancer. For each cancer, three risk subgroups were identified by stratifying patients according to
initial stage, and prediction probabilities were generated based on the factors most closely related to 5-year disease-specific
death. Separate subgroup probabilities were merged to form a single composite index, and its predictive efficacy was
assessed by several measures, including the area (AUC) under its receiver operating characteristic (ROC) curve. The patient-
centered methodology achieved an AUC of 0.867 in the prediction of 5-year disease-specific death, compared with 0.787
using the AJCC staging classification alone. When applied to breast cancer patients, it achieved an AUC of 0.907, compared
with 0.802 using the AJCC staging classification alone. A prognostic algorithm produced from a randomly selected training
subsample of 800 melanoma patients preserved 92.5% of its prognostic efficacy (as measured by AUC) when the same
algorithm was applied to a validation subsample containing the remaining patients. Finally, the tailored prognostic
approach enhanced the identification of high-risk candidates for adjuvant therapy in melanoma. These results describe a
novel patient-centered prognostic methodology with improved predictive efficacy when compared with AJCC stage alone
in two distinct malignancies drawn from two separate populations.
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Introduction
The art of prognosis has a long history, as physicians have
attempted to understand the clinical behavior of disease. Ancient
Egyptians estimated patient survival in order to arrive at an initial
conclusion of either ‘‘a patient I will treat’’ or ‘‘a patient not to be
treated’’ (the former with a chance to cure and the latter thought
to be incurable). More recently, prognostic models have been
developed using computerized analyses of large databases of
patients with commonly recorded factors in order to predict
outcome. In such factor-centered analyses, results are usually
stated in terms of relative risks, odds ratios and P-values associated
with each factor. In the realm of cancer, staging classifications are
developed from these prognostic analyses and constitute the
primary means of predicting patient outcomes and of making
treatment decisions. However, they are not routinely the products
of patient-centered analyses. Assigning a 5-year survival probabil-
ity to a group of patients in a particular stage of a given
malignancy is not the same as providing a separately tailored
prognostic probability for each individual patient.
Patient-centered analyses take a different approach. Prognostic
conclusions are stated in terms of an individual patient’s
probability of experiencing and/or the time required to experience
some salient event, such as recurrence or death. Prognostic factors
do help to determine these probabilities and elapsed times, but the
factors, themselves, are not the primary focus of the analyses.
Patient-centered success measures must reflect the accuracy of
individual probabilistic predictions rather than the relative potency
of the prognostic factors. In addition, patient-centered prognoses
must identify and exploit the most relevant factors that can drive
clinical decisions for an individual patient. The risk of progression
or death may best be predicted by addressing factors beyond those
incorporated into the staging classification and by analyzing
available prognostic factors in specifically novel ways. In this
manuscript, we developed a patient-centered prognostic method-
ology and applied it to established databases of melanoma and
breast cancer patients to determine its predictive accuracy, when
compared to predicting strictly on the basis of initial stage.
Materials and Methods
Ethics Statement
This prognostic analysis was approved by the institutional
review boards at the University of California, San Francisco, and
at the California Pacific Medical Center. The analysis was based
on a chart review of the majority of patients entered into the
datasets. Consequently, it was deemed minimal risk by these
review committees, and informed consent was not required.
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Written informed consent was obtained from the patients whose
tissues were tested as part of the analysis. These procedures were
approved by the aforementioned institutional review boards.
Study Populations
We accumulated a cohort of 1,222 United States patients,
diagnosed with primary cutaneous melanoma between 1971 and
2006, whose demographic composition appears in Table S1. The
mean and median follow-up times were 7.93 years and 7.44 years,
respectively.
In addition, we had access to a previously described [1] dataset
of 1,225 breast cancer patients from Turku, Finland, with a mean
and median follow-up of 9.97 and 8.5 years, respectively. The
demographic composition of the breast cancer cohort appears in
Table S2.
Analysis of Prognostic Factors
Melanoma. Fifteen prognostic factors were recorded at the
time of diagnosis of primary cutaneous melanoma and distributed
into two prognostic factor groups. The first factor group comprised
six factors, including three histological factors incorporated into
the current AJCC staging classification (i.e., tumor thickness,
ulceration, and mitotic rate) [2], and three clinical factors included
in analyses of the AJCC melanoma staging committee (i.e., age,
gender, and tumor site) [3,4]. The following nine histological
factors were included in a second factor group: histological
subtype, Clark level, presence or absence of microsatellites,
vascular involvement, regression, degree of tumor vascularity,
level of tumor infiltrating lymphocytes, number of positive lymph
nodes, and the within-subgroup initial AJCC stage. The potential
prognostic significance of these factors was previously reviewed
[5]. The manner in which these additional prognostic factors were
defined, measured, and coded was described previously [6,7].
The prognostic impact of nine molecular factors (NCOA3,
SPP1, RGS1, WNT2, FN1, ARPC2, PHIP, POU5, and p65
subunit of NF-kB), constituting a third factor group, was examined
in tissues from 375 of the 1,222 melanoma patients using
immunohistochemical analysis. The individual role of several of
these markers in melanoma progression, including the methods
used for immunohistochemical staining and scoring, was previ-
ously described [8–11]. The prognostic significance of several of
these molecular factors has been validated in other tissue sets or by
other investigators [10,12–14].
Breast Cancer. We performed a similar analysis in our
cohort of 1,225 breast cancer patients. The available prognostic
factors were divided into the following three groups: the first factor
group included patient age, anatomical location of the primary
tumor within the breast, size of the primary tumor along its longest
dimension (in millimeters), mitotic count, and ulceration of the
primary tumor. The second factor group consisted of the following
twelve factors: primary tumor type (ductal or lobular), tumor
grade, necrosis, tubule formation, nuclear pleomorphism, inflam-
mation, estrogen receptor level (fmol./mg.), progesterone receptor
level (fmol./mg.), bilaterality, T scale value, N scale value, and M
scale value. The third factor group consisted of the following two
factors: radiation therapy (yes or no), and type of adjuvant therapy,
if any.
Statistical Analysis
To develop a patient-centered prognostic algorithm for disease-
specific death within 5 years of diagnosis, both the 1,222
melanoma and 1,225 breast cancer patients were first stratified
into three risk-defined subgroups, based on AJCC stage at
diagnosis, if available, or T, N, and/or M stage. In the melanoma
cohort, this resulted in a low-risk subgroup containing 503
patients, an intermediate-risk subgroup containing 423 patients,
and a high-risk subgroup containing 296 patients. In the breast
cancer cohort, the low-risk subgroup encompassed 552 patients,
the intermediate subgroup comprised 387 patients, and the high-
risk subgroup included 286 patients. Stratifying both samples into
these three subgroups served to maintain sufficient subgroup sizes
to support stable statistical estimates, while preserving the rank
order of 5-year survival rates by stage inherent in each cohort.
Then, each prognostic factor was transformed, separately within
each risk subgroup, via the Scale Partitioning and Spacing
Algorithm (SPSA) into a corresponding Univariate Impact
Reflecting Index (UIRI), as described in Methods S1.
For each of the nine prognostic factor group and patient risk
subgroup combinations, an individualized prognostic algorithm
was developed (described in Methods S1). The algorithm was
based on the logistic regression analysis whose dependent variable
was experience or non-experience of disease-specific death within
five years of diagnosis and whose independent variables were the
UIRI values calculated for the risk factors and patient subgroup
constituting that combination. A composite prognostic algorithm
was then constructed by merging the logistic regression outputs of
the three patient risk subgroups, when all risk factors (i.e., their
UIRI values) were used as independent variables of the regression.
The prognostic efficacy of the composite algorithm was assessed
using three measures: the AUC generated by a receiver operating
characteristic (ROC) analysis; its mean individual probabilistic
prediction error; and its minimally achievable misclassification
rate (the latter two are defined in Methods S1). All reported P
values are two-sided.
Results
To develop a patient-centered approach, we analyzed a cohort
of 1,222 patients with primary cutaneous melanoma (Table S1)
and a separate cohort of 1,225 patients with breast cancer (Table
S2).
A Tailored Prognostic Model for Melanoma
Initially, we stratified our melanoma cohort, based primarily on
initial stage, into three patient subgroups. The low-risk subgroup
had a 94.6% 5-year disease-specific survival (DSS), the interme-
diate-risk subgroup had a 75.4% 5-year DSS, and the high-risk
subgroup had a 49.3% 5-year DSS. The three subgroups had
significantly different survival characteristics, when assessed by 5-
yr DSS (Kruskal-Wallis test corrected for tied observations,
P,0.001) and by Kaplan-Meier analysis (Log-rank test,
P,0.001, Fig. 1A).
For each prognostic factor group and patient subgroup we
developed a separate prognostic algorithm that best predicted 5-
year disease-specific death. Separate algorithms were merged into
a single, composite algorithm for each risk subgroup. Each
composite algorithm produced a corresponding composite prog-
nostic index. Values of this index were individual probabilities of
5-year disease-specific death assigned by the composite prognostic
algorithm to each patient. Under an ROC analysis, the composite
index generated an AUC of 0.867 (Fig. 2A). It was able to
correctly predict 84.0% of the 5-year disease-specific events,
resulting in a misclassification rate of 16.0%.
We compared the prognostic efficacy of the composite index
with several other prognostic methodologies. Initially, we assessed
the six routinely available prognostic factors by estimating
individual probabilities of 5-year disease-specific death from a
Tailored Prognostic Methodology
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multiple logistic regression of these factors. This produced an
AUC of 0.762, and a misclassification rate of 21.2% (Table 1).
Next, we performed a dummy-variable logistic regression using
AJCC stage, alone, to assign 5-year disease-specific death
probabilities in our melanoma sample and determined its
prognostic efficacy. This analysis yielded an AUC of 0.787
(Fig. 2A and Table 1) and reduced mean absolute probabilistic
prediction error (matched-pairs T-test, P,0.001, Table 1).
Then, we included the six prognostic factors and used initial
AJCC stage to stratify the 1,222 patients into the three risk
subgroups. The individual probability estimates generated by the
multiple logistic regression analyses for each subgroup were
merged, resulting in an AUC of 0.823, and further reduced mean
absolute probabilistic error (matched-pairs T-test, P,0.001,
Table 1).
We then incorporated the eighteen additional prognostic factors
and formed the composite algorithm described above to generate
the final prognostic index. Enhancing the model in these ways
increased the AUC to 0.867 and further reduced the mean
absolute probabilistic error (matched-pairs T-test, P,0.001,
Fig. 2A and Table 1).
We then constructed a separate weighted index designed to
reflect the relative predictive potency of each prognostic factor in
each risk subgroup (Table S3). Thus, tumor thickness, mitotic rate,
tumor vascularity, RGS1 expression level, and FN1 expression
level were uniformly potent predictors, with positive weights in all
of the three subgroups.
A Tailored Prognostic Model for Breast Cancer
We used the identical procedure to develop personalized
predictions of 5-year DSS for breast cancer patients, using data
from our cohort of 1,225 patients. We stratified the overall cohort
into three risk subgroups, based on the AJCC staging criteria for
breast cancer. The low-risk subgroup had a 88.6% 5-year DSS,
the intermediate-risk subgroup had a 60.2% 5-year DSS, and the
high-risk subgroup had a 19.9% 5-year DSS. The three prognostic
subgroups had significantly different survival characteristics, when
assessed by 5-yr DSS (Kruskal-Wallis test corrected for tied
observations, P,0.001) and by Kaplan-Meier analysis (Log-rank
test, P,0.001, Fig. 1B).
Application of the patient-centered approach to breast cancer
patients generated an AUC of 0.907 (Fig. 2B). The final composite
prognostic index developed for breast cancer was able to correctly
predict 84.1% of the 5-year disease-specific deaths, resulting in a
misclassification rate of 15.9%.
The initial factor-centered analysis consisted of five prognostic
factors that were as comparable as possible to the factors used in
the melanoma analysis (except for gender, as all patients were
women). Combining these factors via logistic regression and
developing an individually tailored probability of 5-year disease-
specific death resulted in an AUC of 0.743 (Table 2).
Next, we performed a dummy-variable logistic regression using
AJCC stage, alone, to assign 5-year disease-specific death
probabilities due to breast cancer and determined its prognostic
efficacy. This analysis yielded an AUC of 0.802 (Fig. 2B) and
reduced mean absolute probabilistic prediction error (matched-
pairs T-test, P,0.001, Table 2).
We then stratified the cohort using the three prognostic
subgroups with distinct DSS. The individual probability estimates
generated by the multiple logistic regression analyses for each
subgroup were merged, resulting in an AUC of 0.880 and a
further reduced mean absolute probabilistic error (matched-pairs
T-test, P,0.001, Table 2).
Finally, we incorporated fourteen additional prognostic factors
and formed the composite algorithm previously described to
generate the final prognostic index. This procedure increased the
AUC to 0.907 and further reduced the mean absolute probabilistic
error (matched-pairs T-test, P,0.001, Fig. 2B and Table 2).
A separate weighted index similarly identified prognostic factors
that were relatively potent predictors of 5-year disease-specific
death in each risk subgroup (Table S4). Thus, mitotic rate and
tumor grade were uniformly potent predictors, with positive
weights in all of the three subgroups.
A Split-Sample Validation of the Tailored Prognostic
Methodology in Melanoma
In order to ascertain the reliability of the procedure used to
construct our composite prognostic algorithm, we randomly split
our sample of melanoma patients into a training subsample of 800
and a validation subsample of the remaining patients. Patients in
the two subsamples were divided into three separate risk
subgroups, using exactly the same criteria used to stratify patients
in the total sample.
Next, we constructed a composite algorithm from the training
subsample, using the same procedure applied to the entire cohort.
Figure 1. Panel A. Kaplan-Meier analysis of DSS by prognostic
subgroup in the melanoma cohort. Panel B. Kaplan-Meier analysis
of DSS by prognostic subgroup in the breast cancer cohort.
doi:10.1371/journal.pone.0056435.g001
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Figure 2. Panel A. ROC plots of 5-year melanoma-specific death probabilities estimated by different logistic regression analyses.
Panel B. ROC plots of 5-year breast cancer-specific death probabilities estimated by different logistic regression analyses. In each panel, curve 1
represents the ROC plot using initial AJCC stage (unstratified), curve 2 the ROC plot stratified by AJCC stage, and curve 3 the ROC plot determined by
the composite weighted index.
doi:10.1371/journal.pone.0056435.g002
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This algorithm was quite similar to the algorithm produced for the
total sample. The composite index generated by the composite
prognostic algorithm constructed from the training subsample was
found to be superior to the corresponding probabilistic indices
derived from the six routinely available prognostic factors and
from initial AJCC stage in both the training and validation
subsamples by ROC analysis (data not shown).
Finally, we compared the prognostic efficacies achieved by the
composite algorithm, when applied to the training and validation
subsamples. When applied to the 800 patients in the training
subsample, it achieved an AUC of 0.853. When applied to the
remaining patients in the validation subsample, the same
composite algorithm achieved an AUC of 0.789. Thus, the
algorithm developed from the training subsample preserved 92.5%
of its prognostic efficacy, as measured by AUC, when applied to
the validation subsample.
Utility of Tailored Prognostic Methodology for Identifying
Patients Subsets for Adjuvant Therapy
We then aimed to assess whether the tailored methodology
could be utilized to identify specific prognostic patient subsets for
systemic adjuvant therapy. High-dose interferon alpha (IFN) has
been the standard adjuvant therapy for melanoma for over a
decade. The traditional eligibility criteria for IFN [15–17] include
patients with thick primary melanoma (greater than 4.0 mm thick)
or node-positive disease. Using these criteria, we identified 492
patients in our melanoma cohort eligible for IFN treatment. We
then identified an identical number of patients using our
methodology with the highest individual probabilities of 5-year
disease-specific death (excluding stage IV patients). These two
subsamples were combined, and subsequently partitioned into
three mutually exclusive subsets: 129 patients identified only by
standard IFN eligibility criteria (group 1); 363 patients identified
by both criteria (group 2); and 129 patients identified only by our
methodology (group 3). Their survival was analyzed using Kaplan-
Meier analysis. Whereas the DSS of groups 2 and 3 was not
significantly different, the DSS of group 1 was significantly longer
compared with either group 2 or 3 by (Fig. 3, log-rank test,
P,0.001).
Discussion
In this manuscript, we describe a patient-centered methodology
to determine the prognosis associated with two common and
potentially fatal cancers. We demonstrate that use of this approach
results in significant improvements over the use of standard
prognostic methodologies, when predictive efficacy is measured
using AUC, probabilistic prediction errors, and misclassification
rates in the prediction of 5-year death due to melanoma or breast
cancer.
Use of our tailored prognostic approach resulted in AUC
increases in predicting both 5-year cancer-specific deaths. We also
demonstrate that use of this methodology results in the improved
identification of high-risk candidates for adjuvant therapy in
melanoma.
We achieved these improvements: (i) by first stratifying patients
into separate risk groups according to initial stage and by then
executing analyses, separately, for each group; (ii) by pre-
converting all prognostic factors into comparably calibrated
indices (UIRIs); (iii) by handling missing observations in a manner
that does not require eliminating patients with sparse data from
the analysis; and (iv) by incorporating additional prognostic factors
not routinely captured in staging schemes, using these same three
methodological devices.
In addition, our patient-centered approach is different from
traditional prognostic analyses in a number of other ways.
Traditional analyses typically focus on the relative prognostic
Table 1. Comparison of predictive accuracy achieved in melanoma through differing prognostic methodologies (N = 1,222).
Prognostic Methodology AUC Mean Reduction T value P value
Six traditional prognostic factors (unstratified logistic regression) 0.762 N/A N/A N/A
AJCC stage (dummy variable logistic regression) 0.787 0.015 3.67 ,0.001
Six traditional prognostic factors (logistic regression stratified by
AJCC stage)
0.823 0.016 4.35 ,0.001
Composite index (logistic regression, stratified by AJCC stage,
incorporating 18 additional factors)
0.867 0.033 9.62 ,0.001
Note: T values and accompanying 2-tail P values refer to reductions in mean absolute probabilistic error achieved relative to the prognostic methodology tabled in the
line immediately above, where each matched-pair T test is applied to the indicated 1,222 matched pairs of individual probabilistic prediction errors.
doi:10.1371/journal.pone.0056435.t001
Table 2. Comparison of predictive accuracy achieved in breast cancer through differing prognostic methodologies (N = 1,225).
Prognostic Methodology AUC Mean Reduction T value P value
Five prognostic factors (unstratified logistic regression) 0.743 N/A N/A N/A
AJCC stage (dummy variable logistic regression) 0.802 0.052 7.08 ,0.001
Five prognostic factors (logistic regression stratified by AJCC
stage)
0.880 0.064 11.69 ,0.001
Composite index (logistic regression, stratified by AJCC stage,
incorporating 14 additional factors)
0.907 0.037 9.77 ,0.001
Note: T values and accompanying 2-tail P values refer to reductions in mean absolute probabilistic error achieved relative to the prognostic methodology tabled in the
line immediately above, where each matched-pair T test is applied to the indicated 1,225 matched pairs of individual probabilistic prediction errors.
doi:10.1371/journal.pone.0056435.t002
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potency of various factors using multivariate Cox or logistic
regression. Yet possessing independent statistical significance does
not guarantee that a factor will be prognostically useful for an
individual patient [18]. In addition, staging schemes typically
provide a survival estimate over a defined time period (e.g., 5- or
10-year survival) for all patients in a distinct substage of the cancer.
By contrast, our approach converts prognostic output into tailored
individual probabilities of some salient event, such as 5-year
disease-specific death. This is the essence of the patient-centered
approach. It focuses on individual patient outcomes rather than on
the comparative potency of specific prognostic factors. Further-
more, it generates a separate probability of 5-year disease-specific
death for each individual patient. It represents a shift in focus from
the specific prognostic factors present in certain subgroups of
patients to individual patient outcomes. While the role played by
prognostic factors remains crucial, the factors now serve as the
basis on which individually tailored patient probabilities are
calculated. Prognostic factors are no longer the focus of the
analysis in terms of which final conclusions are stated.
Since prognostic research usually focuses on identifying factors
that provide statistically independent impact with a significant P
value, whether or not alternative analytical procedures can
improve prognostic efficacy at the level of individual patient
outcomes is infrequently discussed and rarely demonstrated. Here
we demonstrate the improvement in AUC achieved by our
patient-centered prognostic approach, when compared with the
use of AJCC stage in two different malignancies.
Developing tailored prognostic models is an important goal that
has been examined by other groups. Cochran et al. [19] identified
factors that emerged from logistic regression in a dataset of 1,042
melanoma patients, and developed individualized probabilistic risk
estimates. Recently, the AJCC Melanoma Task Force developed
an electronic tool to predict survival of localized melanoma using
multivariate Cox regression analyses of five routinely available
prognostic factors [20]. The survival estimates developed in a
dataset of 14,760 patients were validated in an independent cohort
of 10,974 patients. Significant procedural differences preclude
comparisons with the patient-centered methodology described
here. Importantly, no details were provided regarding the
prognostic efficacy of their approach. However, in our cohort,
the patient-centered approach was superior in prognostic accuracy
when compared with the use of routinely available prognostic
factors, alone.
Based on the results presented here, our patient-centered
methodology may be of broad-based utility in making individually
tailored prognoses for other cancers, as well as for other chronic
diseases with significant morbidity. We utilized this methodology
to improve prognostic accuracy and risk assessment for adjuvant
therapy, but the same approach could also be used to identify
patients with differential response to therapy. This may be
especially relevant in the current debate to limit financial resources
for health care. Methodologies that improve prognostic accuracy
might also be useful in identifying patients who would benefit from
receiving expensive and/or toxic therapies for chronic medical
conditions.
Our prognostic approach enables the determination of individ-
ualized prognoses, even when values for many factors are missing.
While it is helpful to have information for all prognostic factors,
this is not practical for each individual patient. The patient-
centered approach enables the determination of an individual’s
prognosis, based on whatever data are available. This is in contrast
to a typical multivariate logistic or Cox regression, in which
complete information on all prognostic factors is typically required
for a given patient to be included in the analysis. In addition, our
methodology identifies factors of greatest prognostic significance to
distinct risk subgroups of patients and suggests which factors (that
may be missing) would be most useful to include in a patient’s
pathology report (and prognostic assessment).
Datasets for the two malignancies selected to illustrate our
patient-centered methodology were not population based. While
Figure 3. Kaplan-Meier analysis of DSS of high-risk patients identified by traditional eligibility for high-dose IFN only (curve 1),
those identified by both criteria (curve 2), and those identified by the tailored prognostic model only (curve 3).
doi:10.1371/journal.pone.0056435.g003
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population-based datasets are preferable in factor-centered anal-
yses, it is more important in the patient-centered approach to
identify patients who are prognostically ‘‘similar’’ to a particular
patient whose prognosis is being determined. This distinction is
another of the salient implications of moving from a strictly factor-
centered to a patient-centered approach. However, in order to
compile a comprehensive set of reference strata containing
‘‘similar’’ patients, it will be necessary to replicate this method-
ology in larger datasets that sample multiple strata of a general
population with a given malignancy.
An important limitation of our patient-centered methodology is
the possibility of statistical over-fitting. The same devices
incorporated in the methodology that contribute to its improved
prognostic accuracy also risk over-fitting the prognostic algorithm
to whatever empirical observations are used as training data. To
compensate for this, built-in protections against over-fitting
include the admissibility criteria applied before introducing a
candidate prognostic factor into the analysis and the minimum
partition sizes established by the algorithm-generating procedure.
It is important to note that much of the improvement in
predictive accuracy achieved by our methodology cannot reason-
ably be attributed to over-fitting. A substantial portion was
realized simply by analyzing the modest number of routinely
available prognostic and staging parameters in a different manner,
prior to incorporating additional factors within the analyses (rows
1 and 2 vs. row 3 in Tables 1 and 2, respectively).
We have departed from the traditional approach to validating
individual prognostic markers in which separate training and
validation cohorts are used. Rather, we have developed a novel
methodology, specifically designed to make prognostic predictions
at the individual patient level. This methodology was then shown
to improve prognostic accuracy (when compared with initial stage)
in two data sets drawn from distinct populations and involving
different cancers. In addition, a split-sample reliability analysis of
the melanoma cohort revealed that a significant proportion
(greater than 90%) of the prognostic accuracy achieved was
retained in the validation subsample. Ultimately, however, our
methodology would need to be applied to even larger data sets
(several thousands of patients) both to mitigate excessive over-
fitting and to produce a practically useful composite prognostic
algorithm that could be used to make individual patient
predictions.
Our study differs in its focus from important recent studies
aimed at measuring the improvements in prognostic efficacy
realizable from adding new biomarkers, especially when AUC is
inadequate in its ability to detect changes in absolute risk [21–24].
In the realm of cancer, these techniques have been used to assess
breast cancer risk [25]. In our analysis, both the use of ROC plots
and probabilistic prediction methods proved adequate to demon-
strate the improved efficacy of our tailored prognostic methodol-
ogy. More importantly, our methodology goes beyond measuring
predictive improvements. It offers procedures and devices by
which such improvements can be realized.
In conclusion, we have developed a methodology to assign
individualized probabilities to a specified focal event (e.g. five-year
disease-specific death). This approach resulted in significant
improvements in predictive accuracy in two different malignancies
when compared with the use of routine prognostic methodologies,
and can be used to tailor discussions regarding prognosis and
therapy for an individual patient.
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